BioSpace News Archive

SUGAR LAND, TX / ACCESSWIRE / December 10, 2020 / Neutra Corp. (OTC PINK:NTRR) retail subsidiary VIVIS is launching its pain cream which has been in its test market for the past few months. “It took a while to get the formula down just the way we like it,” said Neutra CEO Sydney Jim. “Our pain cream is a tad more mild in menthol but we have doubled the concentration of CBD per application and added a few more ingredients that are great for pain management.” VIVIS products

Cerner Corporation, a global health care technology company, announced it’s building on the recent collaboration with Xealth to offer health systems new centralized digital ordering and monitoring for clients.

Avid Bioservices, Inc., a dedicated biologics contract development and manufacturing organization working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, announced the pricing of an underwritten public offering of 3,333,335 shares of its common stock at a price to the public of $9.00 per share.

Evommune, Inc., a private R&D company and innovation engine in chronic inflammation, and Axcelead Drug Discovery Partners, Inc. (Axcelead), a Japanese solution provider in drug discovery research, today announced they have started an exclusive partnership for a late-stage discovery program.

Dr. Paik’s deep expertise in microfluidics and product development to be applied in advancing Molecular Assemblies’ breakthrough enzymatic DNA synthesis technology into a commercial platform

Today, Ginkgo Bioworks , Inc. (“Ginkgo”) and Octant, Inc (“Octant”) announced a partnership to grow critical diagnostic testing capacity to address the COVID-19

MSN Labs, based in Hyderabad India, recently received FDA approval to market their generic versions of Toremifene 60mg tablets, (AB rated to Kyowa Kirin’s Fareston©) & Aminocaproic Acid 500mg tablet, (AB rated Clover’s Amicar©) under the Novadoz label.

Molecular diagnostics company Lucence today announced that the company’s Palo Alto laboratory received certification from the U.S. Department of Health and Human Services’ Centers for Medicare & Medicaid Services (CMS) under the Clinical Laboratory Improvement Amendments (CLIA) of 1988.

BioSkryb’s grant program will support up to two researchers to empower their discoveries through ResolveDNA™, the company’s novel whole genome amplification products that provide unprecedented genome coverage and accuracy ResolveDNA incorporates BioSkryb’s primary template-directed amplification (PTA) technology, which was created to address the inherent challenges of single-cell genomics by producing high-quality gene sequencing data DURHAM,

Agreements made with (i) Oldest and one of the top children’s hospitals in the United States and (ii) Prominent Research Scientist at Vanderbilt University Medical Center